In vivo differential brain clearance and catabolism of monomeric and oligomeric alzheimer's aβ protein

Frontiers in Aging Neuroscience

Volumn 8, Issue SEP, 2016, Pages

  McIntee, Farron L ^a,b   Giannoni, Patrizia ^a,c   Blais, Steven ^a,d   Sommer, George ^a   Neubert, Thomas A ^a   Rostagno, Agueda ^a   Ghiso, Jorge ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIV MONTPELLIER   (France)

^d Otsuka Pharmaceuticals   (United States)

Author keywords

A brain efflux; A brain homeostasis; Cerebrospinal fluid; Local proteolytic degradation; Stereotaxic intra cerebral injection; Targeted mass spectrometric analysis

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; MONOMER; OLIGOMER;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN INTERSTITIAL FLUID; CARBOXY TERMINAL SEQUENCE; CEREBROSPINAL FLUID; CHOROID PLEXUS; CONTROLLED STUDY; IN VIVO STUDY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OLIGOMERIZATION; PATHOGENESIS; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN METABOLISM;

EID: 84992045356     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2016.00223     Document Type: Article

References (108)

1. Abbott, N. J. (2002). Astrocyte-endothelial interactions and blood-brain barrier permeability. J. Anat. 200, 629-638. doi: 10.1046/j.1469-7580.2002.00064.x.
2. Abbott, N. J., Patabendige, A. A., Dolman, E. M., Yusof, S. R., and Begley, D. J. (2010). Structure and function of the blood-brain barrier. Neurobiol. Dis. 37, 13-25. doi: 10.1016/j.nbd.2009.07.030.
3. Allt, G., and Lawrenson, J. G. (2001). Pericytes: cell biology and pathology. Cells Tissues Organs 169, 1-11. doi: 10.1159/000047855.
4. Armulik, A., Abramsson, A., and Betsholtz, C. (2005). Endothelial/pericyte interactions. Circ. Res. 97, 512-523. doi: 10.1161/01.RES.0000182903.16652.d7.
5. Aspelund, A., Antila, S., Proulx, S. T., Karlsen, T. V., Karaman, S., Detmar, M., et al. (2015). A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J. Exp. Med. 212, 991-999. doi: 10.1084/jem.20142290.
6. Bading, J., Yamada, S., Mackic, J. B., Kirkman, L., Miller, C. A., Calero, M., et al. (2002). Brain clearance of Alzheimer's amyloid-β40 in the squirrel monkey: a SPECT study in a primate model of cerebral amyloid angiopathy. J. Drug Target 10, 359-368. doi: 10.1080/10611860290031831.
7. Baig, S., Joseph, S. A., Tayler, H., Abraham, R., Owen, M. J., Williams, J., et al. (2010). Distribution and expression of picalm in Alzheimer disease. J. Neuropathol. Exp. Neurol. 69, 1071-1077. doi: 10.1097/NEN.0b013e3181f52e01.
8. Bakker, E. N., Bacskai, B. J., Arbel-Ornath, M., Aldea, R., Bedussi, B., Morris, A. W., et al. (2016). Lymphatic clearance of the brain: perivascular, paravascular and significance for neurodegenerative diseases. Cell. Mol. Neurobiol. 36, 181-194. doi: 10.1007/s10571-015-0273-8.
9. Behl, M., Zhang, Y., Monnot, A. D., Jiang, W., and Zheng, W. (2009). Increased b-amyloid levels in the choroid plexus followig lead exposure and the involvement of low-density lipoprotein receptor protein-1. Toxicol. Appl. Pharmacol. 240, 245-254. doi: 10.1016/j.taap.2009.05.024.
10. Bell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., et al. (2007). Transport pathways for clearance of human Alzheimer's amyloid β-peptide and apolipoproteins E and J in the mouse central nervous system. J. Cereb. Blood Flow Metab. 27, 909-918. doi: 10.1038/sj.jcbfm.9600419.
11. Bu, G., Maksymovitch, E. A., Nerbonne, J. M., and Schwartz, A. L. (1994). Expression and function of the low density lipoprotein receptor-related protein (LRP) in mammalian central neurons. J. Biol. Chem. 269, 18521-18528.
12. Busciglio, J., Pelsman, A., Wong, C., Pigino, G., Yuan, M., Mori, H., et al. (2002). Altered metabolism of the amyloid β precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 33, 677-688. doi: 10.1016/S0896-6273(02)00604-9.
13. Calero, M., and Ghiso, J. (2005). "Radioiodination of Aβ peptides," in Amyloid Proteins: Methods and Protocols, eds E. M. Sigurdsson (Totowa, NJ: Humana Press), 325-348.
14. Candela, P., Gosselet, F., Saint-Pol, J., Sevin, E., Boucau, M. C., Boulanger, E., et al. (2010). Apical-to-basolateral transport of amyloid-β peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein. J. Alzheimers. Dis. 22, 849-859. doi: 10.3233/JAD-2010-100462.
15. Caughey, B., and Lansbury, P. T. (2003). Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the inocent bystanders. Annu. Rev. Neurosci. 26, 267-298. doi: 10.1146/annurev.neuro.26.010302.081142.
16. Cecchelli, R., Berezowski, V., Lundquist, S., Culot, M., Renftel, M., Dehouck, M. P., et al. (2007). Modelling of the blood-brain barrier in drug discovery and development. Nat. Rev. Drug Discov. 6, 650-661. doi: 10.1038/nrd2368.
17. Chesser, A. S., Pritchard, S. M., and Johnson, G. V. (2013). Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease. Front. Neurol. 4:122. doi: 10.3389/fneur.2013.00122.
18. Deane, R., Bell, R. D., Sagare, A., and Zlokovic, B. (2009). Clearance of amyloid-β peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol. Dis. Drug Targets 8, 16-30. doi: 10.2174/187152709787601867.
19. Deane, R., Sagare, A., and Zlokovic, B. V. (2008). The role of the cell surface LRP and soluble LRP in blood-brain barrier Ab clearance in Alzheimer's disease. Curr. Pharmac. Des. 14, 1601-1605. doi: 10.2174/138161208784705487.
20. Deane, R., Wu, Z., and Zlokovic, B. (2004). RAGE (Yin) versus LRP (yang) balance regulates Alzheimer Amyloid b-peptide clearance through transport across the blood-brain-barrier. Stroke 35, 2628-2631. doi: 10.1161/01.STR.0000143452.85382.d1.
21. Deane, R., Du Yan, S., Submamaryan, R. K., LaEue, B., Jovanovic, S., Hogg, E., et al. (2003). RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation on the brain. Nat. Med. 9, 907-913. doi: 10.1038/nm890.
22. De Strooper, B. (2010). Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol. Rev. 90, 465-494. doi: 10.1152/physrev.00023.2009.
23. Devi, L., and Ohno, M. (2012). Mitochondrial dysfunction and accumulation of the β-secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic mice. Neurobiol. Dis. 45, 417-424. doi: 10.1016/j.nbd.2011.09.001.
24. Dietrich, M. O., Spuch, C., Antequera, D., Rodal, I., de Yebenes, J. G., Molina, J. A., et al. (2008). Megalin mediates the transport of leptin across the blood-CSF barrier. Neurobiol. Aging 26, 902-912. doi: 10.1016/j.neurobiolaging.2007.01.008.
25. Di Marco, L. Y., Venneri, A., Farkas, E., Evans, P. C., Marzo, A., and Frangi, A. F. (2015). Vascular dysfunction in the pathogenesis of Alzheimer's disease-A review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiol. Dis. 82, 593-606. doi: 10.1016/j.nbd.2015.08.014.
26. Fossati, S., Cam, J., Meyerson, J., Mezhericher, E., Romero, I. A., Couraud, P.-O., et al. (2010). Differential activation of mitochondrial apoptotic pathways by vasculotropic amyloid-β variants in cells composing the cerebral vessel walls. FASEB J. 24, 229-241. doi: 10.1096/fj.09-139584.
27. Fossati, S., Giannoni, P., Solesio, M. E., Cocklin, S. L., Cabrera, E., Ghiso, J., et al. (2016). The carbonic anhydrase inhibitor methazolamide prevents amyloid β-induced mitochondrial dysfunction and caspase activation protecting neuronal and glial cells in vitro and in the mouse brain. Neurobiol. Dis. 86 29-40. doi: 10.1016/j.nbd.2015.11.006.
28. Galvan, V., and Hart, M. J. (2016). Vascular mTOR-dependent mechanisms linking the control of aging to Alzheimer's disease. Biochim. Biophys. Acta 1862, 992-1007. doi: 10.1016/j.bbadis.2015.11.010.
29. Ghersi-Egea, J. F., Gorevic, P., Ghiso, J., Frangione, B., Patlak, C. S., and Fenstermacher, J. (1996). Fate of cerebrospinal fluid-borne amyloid b-peptide: rapid clearence into blood and appreciable accumulation by cerebral arteries. J. Neurochem. 67, 880-883. doi: 10.1046/j.1471-4159.1996.67020880.x.
30. Ghiso, J., and Frangione, B. (2002). Amyloidosis and Alzheimer's disease. Adv. Drug Delivery Rev. 54, 1539-1551. doi: 10.1016/S0169-409X(02)00149-7.
31. Ghiso, J., Holton, J., Miravalle, L., Calero, M., Lashley, T., Vidal, R., et al. (2001). Systemic amyloid deposits in Familial British Dementia. J. Biol. Chem. 276, 43909-43914. doi: 10.1074/jbc.M105956200.
32. Ghiso, J., Shayo, M., Calero, M., Ng, D., Tomidokoro, Y., Gandy, S. E., et al. (2004). Systemic catabolism of Alzheimer's Aβ40 and Aβ42. J. Biol. Chem. 279, 45897-45908. doi: 10.1074/jbc.M407668200.
33. Haass, C., and Selkoe, D. J. (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112. doi: 10.1038/nrm2101.
34. Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., et al. (2009). Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 41, 1088-1093. doi: 10.1038/ng.440.
35. Hawkes, C. A., Härtig, W., Kacza, J., Schliebs, R., Weller, R. O., Nicoll, J. A., et al. (2011). Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathol. 121, 431-443. doi: 10.1007/s00401-011-0801-7.
36. Hernandez-Guillamon, M., Mawhirt, S., Blais, S., Montaner, J., Neubert, T. A., Rostagno, A., et al. (2015). Sequential amyloid-β degradation by the matrix metalloproteases MMP-2 and MMP-9. J. Biol. Chem. 290, 15078-15091. doi: 10.1074/jbc.M114.610931.
37. Holtzman, D. M., Morris, J. C., and Goate, A. M. (2011). Alzheimer's disease: the challenge of the second century. Sci. Transl. Med. 3:77sr1. doi: 10.1126/scitranslmed.3002369.
38. Iliff, J. J., Chen, M. J., Plog, B. A., Zeppenfeld, D. M., Soltero, M., Yang, L., et al. (2014). Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. J. Neurosci. 34, 16180-16193. doi: 10.1523/JNEUROSCI.3020-14.2014.
39. Iliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., et al. (2012). A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci. Transl. Med. 4:147ra111. doi: 10.1126/scitranslmed.3003748.
40. Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., and Selkoe, D. J. (2011). Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc. Natl. Acad. Sci. U.S.A. 108, 5819-5824. doi: 10.1073/pnas.1017033108.
41. Johanson, C. E., Duncan, J. A., Klinge, P. M., Brinker, T., Stopa, E. G., and Silverberg, G. D. (2008). Multiplicity of cerebrospinal fluid functions: new challenges in health and disease. Cerebrospinal Fluid Res. 5:10 doi: 10.1186/1743-8454-5-10.
42. Jungbauera, L. M., Yua, C., Laxtona, K. J., and LaDu, M. J. (2009). Preparation of fluorescently-labeled amyloid-β peptide assemblies: the effect of fluorophore conjugation on structure and function. J. Mol. Recognit. 22, 403-413. doi: 10.1002/jmr.948.
43. Kane, M. D., Lipinski, W. J., Callahan, M. J., Bian, F., Durham, R. A., Schwarz, R. D., et al. (2000). Evidence for seeding of β-amyloid by intracerebral infusion of Alzheimer brain extracts in β-amyloid precursor protein-transgenic mice. J. Neurosci. 20, 3606-3611.
44. Kanekiyo, T., Cirrito, J. R., Liu, C. C., Shinohara, M., Li, J., Schuler, D. R., et al. (2013). Neuronal clearance of amyloid-β by endocytic receptor LRP1. J. Neurosci. 33, 19276-19283. doi: 10.1523/JNEUROSCI.3487-13.2013.
45. Kanekiyo, T., Liu, C. C., Shinohara, M., Li, J., and Bu, G. (2012). LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer's amyloid-β. J. Neurosci. 32, 16458-16465. doi: 10.1523/JNEUROSCI.3987-12.2012.
46. Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K. H., et al. (1987). The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733-736. doi: 10.1038/325733a0.
47. Kheterpal, I., Chen, M., Cook, K. D., and Wetzel, R. (2006). Structural differences in Abeta amyloid protofibrils and fibrils mapped by hydrogen exchange-Mass spectrometry with on-line proteolytic fragmentation. J. Mol. Biol. 361, 785-795. doi: 10.1016/j.jmb.2006.06.066.
48. Koistinaho, M., Lin, S., Wu, X., Esterman, M., Koger, D., Hanson, J., et al. (2004). Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides. Nat. Med. 10, 719-726. doi: 10.1038/nm1058.
49. Kuo, Y. M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., et al. (1996). Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 271, 4077-4081. doi: 10.1074/jbc.271.8.4077.
50. Lambert, J. C., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013). Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat. Genet. 45, 1452-1458. doi: 10.1038/ng.2802.
51. Li, S., Hong, S., Shepardson, N. E., Walsh, D. M., Shankar, G. M., and Selkoe, D. (2009). Soluble oligomers of amyloid β protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62, 788-801. doi: 10.1016/j.neuron.2009.05.012.
52. Liu, L., and Duff, K. (2008). A technique for serial collection of cerebrospinal fluid from the Cisterna Magna in Mouse. J. Vis. Exp. pii:960. doi: 10.3791/960.
53. Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., et al. (2015). Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337-341. doi: 10.1038/nature14432.
54. Lue, L. F., Kuo, Y. M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., et al. (1999). Soluble amyloid β concentration is a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155, 853-862. doi: 10.1016/S0002-9440(10)65184-X.
55. Lustbader, J. W., Cirilli, M., Lin, C., Xu, H. W., Takuma, K., Wang, N., et al. (2004). ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304, 448-452. doi: 10.1126/science.1091230.
56. Lyros, E., Bakogiannis, C., Liu, Y., and Fassbender, K. (2014). Molecular links between endothelial dysfunction and neurodegeneration in Alzheimer's disease. Curr. Alzheimer Res. 11, 18-26. doi: 10.2174/1567205010666131119235254.
57. Mackic, J. B., Stins, M., McComb, J. G., Calero, M., Ghiso, J., Kim, K. S., et al. (1998). Human blood-brain barrier receptors for Alzheimer's amyloid-β 1-40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J. Clin. Invest. 102, 734-743. doi: 10.1172/JCI2029.
58. Mandrekar, S., Jiang, Q., Lee, C. Y., Koenigsknecht-Talboo, J., Holtzman, D. M., and Landreth, G. E. (2009). Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J. Neurosci. 29, 4252-4262. doi: 10.1523/JNEUROSCI.5572-08.2009.
59. Martel, C., Mackic, J. B., Matsubara, E., Governale, S., Miguel, C., Miao, W., et al. (1997). Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid β. J. Neurochem. 69, 1995-2004. doi: 10.1046/j.1471-4159.1997.69051995.x.
60. Masters, C. L., Multhaup, G., Sims, G., Pottigiesser, J., Martins, R. N., and Beyreuther, K. (1985a). Neuronal origin of cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 4, 2757-2763.
61. Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., and Beyreuther, K. (1985b). Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 82, 4245-4249. doi: 10.1073/pnas.82.12.4245.
62. Mattson, M. P. (2004). Pathways towards and away from Alzheimer's disease. Nature 430, 631-639. doi: 10.1038/nature02621.
63. Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., et al. (2010). Decreased clearance of CNS β-amyloid in Alzheimer's disease. Science 330, 1774. doi: 10.1126/science.1197623.
64. May, P., Rohlmann, A., Bock, H. H., Zurhove, K., Marth, J. D., Schomburg, E. D., et al. (2004). Neuronal LRP1 functionally associates with postsynaptic proteins and is required for normal motor function in mice. Mol. Cell Biol. 24, 8872-8883. doi: 10.1128/MCB.24.20.8872-8883.2004.
65. McLean, C. A., Cherny, R. A., Fraser, F. W., Fuller, S. J., Smith, M. J., Beyreuther, K., et al. (1999). Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860-866.
66. Meyer-Luehmann, M., Coomaraswamy, J., Bolmont, T., Kaeser, P. S., Schaefer, C., Kilger, E., et al. (2006). Exogenous induction of cerebral β-amyloidogenesis is governed by agent and host. Science 313, 1781-1784. doi: 10.1126/science.1131864.
67. Miners, J. S., Baig, S., Palmer, J., Palmer, L. E., Kehoe, P. G., and Love, S. (2008). Aβ-degrading enzymes in Alzheimer's disease. Brain Pathol. 18, 240-252. doi: 10.1111/j.1750-3639.2008.00132.x.
68. Morelli, L., Llovera, R., Gonzalez, S. A., Affranchino, J. L., Prelli, F., Frangione, B., et al. (2003). Differential degradation of Aβ genetic variants associated with hereditary dementia or stroke by Insulin-degraded enzyme (IDE). J. Biol. Chem. 278, 23221-23226. doi: 10.1074/jbc.M300276200.
69. Morelli, L., Llovera, R., Ibemdahl, S., and Castaño, E. M. (2002). The degradation of amyloid β as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidosis. Neurochem. Res. 27, 1387-1399. doi: 10.1023/A:1021679817756.
70. Morris, A. W., Carare, R. O., Schreiber, S., and Hawkes, C. A. (2014). The cerebrovascular basement membrane: role in the clearance of β-amyloid and cerebral amyloid angiopathy. Front. Aging Neurosci. 6:251. doi: 10.3389/fnagi.2014.00251.
71. Morris, A. W., Sharp, M. M., Albargothy, N. J., Fernandes, R., Hawkes, C. A., Verma, A., et al. (2016). Vascular basement membranes as pathways for the passage of fluid into and out of the brain. Acta Neuropathol. 131, 725-736. doi: 10.1007/s00401-016-1555-z.
72. Nicholls, R. E., Alarcon, J. M., Malleret, G., Carroll, R. C., Grody, M., Vronskaya, S., et al. (2008). Transgenic mice lacking NMDAR-dependent LTD exhibit deficits in behavioral flexibility. Neuron 58, 104-117. doi: 10.1016/j.neuron.2008.01.039.
73. Nielsen, H. M., Mulder, S. D., Beliën, J. A., Musters, R. J., Eikelenboom, P., and Veerhuis, R. (2010). Astrocytic A β 1-42 uptake is determined by A β-aggregation state and the presence of amyloid-associated proteins. Glia 58, 1235-1246. doi: 10.1002/glia.21004.
74. Nimmerjahn, A., Kirchhoff, F., and Helmchen, F. (2005). Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314-1318. doi: 10.1126/science.1110647.
75. Parikh, I., Fardo, D. W., and Estus, S. (2014). Genetics of PICALM expression and Alzheimer's disease. PLoS ONE 9:e91242. doi: 10.1371/journal.pone.0091242.
76. Poduslo, J. F., Curran, G. L., Sanyal, B., and Selkoe, D. (1999). Receptor-mediated transport of human amyloid-β1-40 and 1-42 at the blood-brain barrier. Neurobiol. Dis. 6, 190-199. doi: 10.1006/nbdi.1999.0238.
77. Portelius, E., Westman-Brinkmalm, A., Zetterberg, H., and Blennow, K. (2006). Determination of β-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J. Proteome Res. 5, 1010-1016. doi: 10.1021/pr050475v.
78. Querfurth, H. W., and LaFerla, F. M. (2010). Alzheimer's disease. N. Engl. J. Med. 362, 329-344. doi: 10.1056/NEJMra0909142.
79. Roberts, K. F., Elbert, D. L., Kasten, T. P., Patterson, B. W., Sigurdson, W. C., Connors, R. E., et al. (2014). Amyloid-β efflux from the central nervous system into the plasma. Ann. Neurol. 76, 837-844. doi: 10.1002/ana.24270.
80. Roher, A., Baudry, J., Chaney, M. O., Kuo, Y.-M., Stine, W. B. J., and Emmerling, M. (2000). Oligomerizaton and fibril asssembly of the amyloid-β protein. Biochim. Byophys. Acta 1502, 31-43. doi: 10.1016/S0925-4439(00)00030-2.
81. Roher, A. E., Chaney, M. O., Kuo, Y. M., Webster, S. D., Stine, W. B., Haverkamp, L. J., et al. (1996). Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J. Biol. Chem. 271, 20631-20635. doi: 10.1074/jbc.271.34.20631.
82. Rostagno, A., Holton, J. L., Lashley, T., Revesz, T., and Ghiso, J. (2010). Cerebral amyloidosis: amyloid subunits, mutants and phenotypes. Cell Mol. Life Sci. 67, 581-600. doi: 10.1007/s00018-009-0182-4.
83. Rostagno, A., Lal, R., and Ghiso, J. (2007). "Protein misfolding, aggregation, and fibril formation: common features of cerebral and non-cerebral amyloid diseases," in The Neurobiology of Alzheimer's Disease, eds D. Dawbarn S. and Allen (Oxford: Oxford University Press), 133-160.
84. Saido, T., and Leissring, M. A. (2012). Proteolytic degradation of amyloid β-protein. Cold Spring Harb. Perspect. Biol. 2:a006379. doi: 10.1101/cshperspect.a006379.
85. Selkoe, D. J. (2001). Clearing the brain's amyloid cobwebs. Neuron 32, 177-180. doi: 10.1016/S0896-6273(01)00475-5.
86. Shankar, G. M., Welzel, A. T., McDonald, J. M., Selkoe, D. J., and Walsh, D. M. (2011). Isolation of low-n amyloid β-protein oligomers from cultured cells, CSF, and brain. Methods Mol. Biol. 670, 33-44. doi: 10.1007/978-1-60761-744-0_3.
87. Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., et al. (2000). Clearance of Alzheimer's amyloid-aβ(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106, 1489-1499. doi: 10.1172/JCI10498.
88. Solito, R., Corti, F., Fossati, S., Mezhericher, E., Donnini, S., Ghiso, J., et al. (2009). Dutch and Arctic mutant peptides of β amyloid(1-40) differentially affect the FGF-2 pathway in brain endothelium. Exp. Cell Res. 315, 385-395. doi: 10.1016/j.yexcr.2008.11.002.
89. Stine, W. B. Jr., Dahlgren, K. N., Krafft, G. A., and LaDu, M. J. (2003). In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis. J. Biol. Chem. 278, 11612-11622. doi: 10.1074/jbc.M210207200.
90. Strazielle, N., Ghersi-Egea, J.-F., Ghiso, J., Dehouck, M.-P., Frangione, B., Patlak, C. S., et al. (2000). In vitro evidence that b-amyloid peptide 1-40 diffuses accross the blood-brain barrier and affects its permeability. J. Neuropathol. Exp. Neurol. 59, 29-38. doi: 10.1093/jnen/59.1.29.
91. Tanzi, R. E. (2012). The genetics of Alzheimer disease. Cold Spring Harbor Perspect. Med. 2:a006296. doi: 10.1101/cshperspect.a006296.
92. Tomidokoro, Y., Lashley, T., Rostagno, A., Neubert, T. A., Bojsen-Moller, M., Braendgaard, H., et al. (2005). Familial danish dementia: co-existence of ADan and Aβ amyloid subunits in the absence of compact plaques. J. Biol. Chem. 280, 36883-36894. doi: 10.1074/jbc.M504038200.
93. Tomidokoro, Y., Rostagno, A., Neubert, T. A., Lu, Y., Rebeck, G. W., Frangione, B., et al. (2010). Iowa variant of familial Alzheimer's disease: accumulation of posttranslationally modified AβD23N in parenchymal and cerebrovascular amyloid deposits. Am. J. Pathol. 176, 1841-1854. doi: 10.2353/ajpath.2010.090636.
94. Ueno, M., Chiba, Y., Murakami, R., Matsumoto, K., Kawauchi, M., and Fujihara, R. (2016). Blood-brain barrier and blood-cerebrospinal fluid barrier in normal and pathological conditions. Brain Tumor Pathol. 33, 89-96. doi: 10.1007/s10014-016-0255-7.
95. Vardy, E. R., Catto, A. J., and Hooper, N. M. (2005). Proteolytic mechanisms in amyloid-β metabolism: therapeutic implications for Alzheimer's disease. Trends Mol. Med. 11, 464-472. doi: 10.1016/j.molmed.2005.08.004.
96. Viana, R. J., Nunes, A. F., Castro, R. E., Ramalho, R. M., Meyerson, J., Fossati, S., et al. (2009). Tauroursodeoxycholic acid prevents E22Q Alzheimer's Abeta toxicity in human cerebral endothelial cells. Cell. Mol. Life Sci. 66, 1094-1104. doi: 10.1007/s00018-009-8746-x.
97. Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., et al. (2002). Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539. doi: 10.1038/416535a.
98. Walsh, D. M., and Selkoe, D. J. (2007). A β oligomers-a decade of discovery. J. Neurochem. 101, 1172-1184. doi: 10.1111/j.1471-4159.2006.04426.x.
99. Wang, Y. J., Zhou, H. D., and Zhou, X. F. (2006). Clearance of amyloid-β in Alzheimer's disease: progress, problems and perspectives. Drug Disc. Today 11, 931-938. doi: 10.1016/j.drudis.2006.08.004.
100. Weller, R. O., Subash, M., Preston, S. D., Mazanti, I., and Carare, R. O. (2008). Perivascular drainage of amyloid-β peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol. 18, 253-266. doi: 10.1111/j.1750-3639.2008.00133.x.
101. Whalen, B. M., Selkoe, D. J., and Hartley, D. M. (2005). Small non-fibrillar assemblies of amyloid B-protein bearing the Arctic mutation induce rapid neuritic degeneration. Neurobiol. Dis. 20, 254-266. doi: 10.1016/j.nbd.2005.03.007.
102. Woods, A. S., Buchsbaum, J. C., Worrall, T. S., Berg, J. M., and Cotter, R. J. (1995). Matrix-Assisted Laser Desorption/lonization of noncovalently bound compounds. Anal. Chem. 67, 4462-4465. doi: 10.1021/ac00120a005.
103. Wyss-Coray, T., Lin, C., Yan, F., Yu, G. Q., Rohde, M., McConlogue, L., et al. (2001). TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice. Nat. Med. 7, 612-618. doi: 10.1038/87945.
104. Wyss-Coray, T., Loike, J. D., Brionne, T. C., Lu, E., Anankov, R., Yan, F., et al. (2003). Adult mouse astrocytes degrade amyloid-β in vitro and in situ. Nat. Med. 9, 453-457. doi: 10.1038/nm838.
105. Zeng, Y., Callaghan, D., Xiong, H., Yang, Z., Huang, P., and Zhang, W. (2012). Abcg2 deficiency augments oxidative stress and cognitive deficits in Tg-SwDI transgenic mice. J. Neurochem. 122, 456-469. doi: 10.1111/j.1471-4159.2012.07783.x.
106. Zlokovic, B., Ghiso, J., Mackic, J. B., McComb, J. G., Weiss, M. H., and Frangione, B. (1993). Blood-brain barrier transport of circulating Alzheimer's amyloid-β. Biochem. Biophys. Res. Comm. 197, 1034-1040. doi: 10.1006/bbrc.1993.2582.
107. Zlokovic, B., Martel, C., Matsubara, E., McCombo, J. G., Zheng, G., McCluskey, R. T., et al. (1996). Gp330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer's Amyloid b at the blood-brain and blood-cerebrospinal fluid barriers. Proc. Natl. Acad. Sci. U.S.A. 93, 4229-4234. doi: 10.1073/pnas.93.9.4229.
108. Zlokovic, B. V. (2011). Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat. Rev. Neurosci. 12, 723-738. doi: 10.1038/nrn3114.